Entering text into the input field will update the search result below

Ligand Pharmaceuticals, Inc.'s (LGND) CEO John Higgins on Q1 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2020 Results Earnings Conference Call May 6, 2020 4:30 PM ET

Company Participants

Patrick O'Brien - Investor Relations

John Higgins - Chief Executive Officer

Matt Korenberg - Executive Vice President, Finance and Chief Financial Officer

Matt Foehr - President and Chief Operating Officer

Conference Call Participants

Matt Hewitt - Craig-Hallum Capital Group

Balaji Prasad - Barclays

Peter Lukas - CJS Securities

Dana Flanders - Guggenheim Securities, LLC

Scott Henry - ROTH Capital Partners


Hello and welcome to Ligand's First Quarter of 2020 Financial Results and Business Update Conference Call. My name is Kathryn and I will be your event specialist today. All lines have been placed on mute to prevent any background noise and please note that today's webcast is being recorded. During the end of the presentation we will have a question-and-answer session. [Operator Instructions]

It is now my pleasure to turn today's program over to Patrick O'Brien, SVP Investor Relations at Ligand's Pharmaceuticals. Patrick, the floor is yours.

Patrick O'Brien

Thank you, Kathryn and welcome everyone. Consistent with recommendations for social distancing, all of our speakers for today's call are in separate locations. So we apologize in advance for any background noise or technology difficulties that we might run into. Speaking for Ligand today will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO. We will be using slides to guide our discussion today. We will also use non-GAAP financial measures and some of our statements will forward-looking.

Additional information concerning risk factors and other matters concerning Ligand can be found in our Ligand's earnings press release, slides and periodic filings with the SEC. Ligand undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.

I would now like

Recommended For You

Comments (3)

Growth Hunter profile picture

It feels like there could be some further upside for LGND. Between the Captisol/remdesivir connection and OmniAB supporting COVID related antibody treatment research, 2020 could turn out to be a nice year for LGND
Truth_AndMovement profile picture
1 minute in and he's talking about the team going above and beyond to support Gilead for the scale up and manufacturing of remdesivir ...they know remdesivir will be a front line medication...japan already approved it. Gilead is going to need a whole lot more captisol...i dig it
General Investment Research profile picture
Yeah. Agree - let's see if there are any insiders picking up shares later. That would be a good signal.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About LGND

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on LGND

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.